Hypertension and cardiac arrhythmias: A consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)

Europace

Volumn 19, Issue 6, 2017, Pages 891-911

  Lip, Gregory Y H ^a,b   Coca, Antonio ^c   Kahan, Thomas ^d   Boriani, Giuseppe ^e   Manolis, Antonis S ^f   Olsen, Michael Hecht ^g   Oto, Ali ^h   Potpara, Tatjana S ⁱ   Steffel, Jan ^j   Marín, Francisco ^k   De Oliveira Figueiredo, Márcio Jansen ^l   De Simone, Giovanni ^m   Tzou, Wendy S ⁿ   Chiang, Chern En ^o   Williams, Bryan ^p   Dan, Gheorghe Andrei ^q   Gorenek, Bulent ^r   Fauchier, Laurent ^s   Savelieva, Irina ^t   Hatala, Robert ^u   Van Gelder, Isabelle ^v   Brguljan Hitij, Jana ^w   Erdine, Serap ^x   Lovic, Dragan ^y   Kim, Young Hoon ^z   Salinas Arce, Jorge ^aa   Field, Michael ^ab   more..

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF BARCELONA   (Spain)

^d DANDERYD HOSPITAL   (Sweden)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h ANKARA NUMUNE HOSPITAL   (Turkey)

ⁱ UNIVERSITY OF BELGRADE   (Serbia)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^l UNIVERSITY OF CAMPINAS   (Brazil)

^m FEDERICO II UNIVERSITY HOSPITAL   (Italy)

ⁿ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^o NATIONAL YANG MING UNIVERSITY   (Taiwan)

^p UNIVERSITY COLLEGE LONDON   (United Kingdom)

^q CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^r ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^s SERVICE DE DERMATOLOGIE   (France)

^t ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^u NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES   (Slovakia)

^v UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^w UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^x ISTANBUL UNIVERSITY   (Turkey)

^y Clinic for Internal Disease Intermedica   (Serbia)

^z Korea University Ansan Hospital   (South Korea)

^aa Perú ORCID: 0000 0002 8595 9549   (Peru)

^ab UNIVERSITY OF WISCONSIN MADISON   (United States)

more..

Author keywords

Arrhythmias; Atrial fibrillation; EHRA consensus document; Hypertension; Left ventricular hypertrophy

Indexed keywords

ARTICLE; ATRIAL FIBRILLATION; ATRIOVENTRICULAR CONDUCTION; BLEEDING; BLOOD PRESSURE REGULATION; CONSENSUS; HEALTH ECONOMICS; HEART ARRHYTHMIA; HEART ATRIUM CONDUCTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RHYTHM; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; MEDICAL SOCIETY; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PRIORITY JOURNAL; RESTING HEART RATE; SICK SINUS SYNDROME; SINUS RHYTHM; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; THROMBOEMBOLISM; BLOOD PRESSURE; COST BENEFIT ANALYSIS; DRUG EFFECT; HEALTH CARE COST; HEART MUSCLE CONDUCTION SYSTEM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SUDDEN CARDIAC DEATH; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE AGENTS; ARRHYTHMIAS, CARDIAC; BLOOD PRESSURE; CONSENSUS; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; HEALTH CARE COSTS; HEART CONDUCTION SYSTEM; HUMANS; HYPERTENSION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 85021828954     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eux091     Document Type: Article

References (189)

1. Benhorin J, Bodenheimer M, Brown M, Case R, Dwyer EM Jr, Eberly S et al; Multicenter Cardiac Research Group. Improving clinical practice guidelines for practicing cardiologists. Am J Cardiol 2015;115:1773-6.
2. Yiu KH, Tse HF. Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications. J Hum Hypertens 2008;22:380-8.
3. Eguchi K, Hoshide S, Schwartz JE, Shimada K, Kario K. Visit-to-visit and ambulatory blood pressure variability as predictors of incident cardiovascular events in patients with hypertension. Am J Hypertens 2012;25:962-8.
4. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA et al. EHRA/ HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace 2016;18:1455-90.
5. Fialova M, Dlugosova K, Okruhlicova L, Kristek F, Manoach M, Tribulova N. Adaptation of the heart to hypertension is associated with maladaptive gap junction connexin-43 remodeling. Physiol Res 2008;57:7-11.
6. Goette A, Bukowska A, Dobrev D, Pfeiffenberger J, Morawietz H, Strugala D et al. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptormediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J 2009;30:1411-20.
7. Canpolat U, Oto A, Hazirolan T, Sunman H, Yorgun H, Sahiner L et al. A prospective DE-MRI study evaluating the role of TGF-beta1 in left atrial fibrosis and implications for outcomes of cryoballoon-based catheter ablation: new insights into primary fibrotic atriocardiomyopathy. J Cardiovasc Electrophysiol 2015;26:251-9.
8. Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. J Am Coll Cardiol 2015;65:2239-51.
9. Spronk HM, De Jong AM, Verheule S, De Boer HC, Maass AH, Lau DH et al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. Eur Heart J 2016;38:38-50.
10. Messerli FH. Hypertension and sudden cardiac death. Am J Hypertens 1999;12:181S-8S.
11. Fukuda K, Kanazawa H, Aizawa Y, Ardell JL, Shivkumar K. Cardiac innervation and sudden cardiac death. Circ Res 2015;116:2005-19.
12. Panikkath R, Reinier K, Uy-Evanado A, Teodorescu C, Gunson K, Jui J et al. Electrocardiographic predictors of sudden cardiac death in patients with left ventricular hypertrophy. Ann Noninvasive Electrocardiol 2013;18:225-9.
13. Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart 2005;91:250-6.
14. Silverberg DS, Oksenberg A. Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? Curr Hypertens Rep 2001;3:209-15.
15. Lavie P, Silverberg D, Oksenberg A, Hoffstein V. Obstructive sleep apnea and hypertension: from correlative to causative relationship. J Clin Hypertens (Greenwich). 2001;3:296-301.
16. Kales A, Bixler EO, Cadieux RJ, Schneck DW, Shaw LC 3rd, Locke TW et al. Sleep apnoea in a hypertensive population. Lancet 1984;2:1005-8.
17. Tribulova N, Okruhlicova L, Novakova S, Pancza D, Bernatova I, Pechanova O et al. Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K()-induced lethal arrhythmias in isolated rat heart. Exp Physiol 2002;87:195-205.
18. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.
19. Vaseghi M, Shivkumar K. The role of the autonomic nervous system in sudden cardiac death. Prog Cardiovasc Dis 2008;50:404-19.
20. Novo S, Barbagallo M, Abrignani MG, Nardi E, Di Maria GU, Longo B et al. Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease. Am J Hypertens 1997;10:843-51.
21. Ijiri H, Kohno I, Yin D, Iwasaki H, Takusagawa M, Iida T et al. Cardiac arrhythmias and left ventricular hypertrophy in dipper and nondipper patients with essential hypertension. Jpn Circ J 2000;64:499-504.
22. Folkeringa RJ, Hartgers J, Tieleman RG, Gorgels AP, Dassen WR, Crijns HJ. Atrial extrasystoles after exercise predict atrial fibrillation in patients with left ventricular hypertrophy. Heart 2006;92:545-6.
23. Larsen BS, Kumarathurai P, Falkenberg J, Nielsen OW, Sajadieh A. Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fibrillation. J Am Coll Cardiol 2015;66:232-41.
24. Ofoma U, He F, Shaffer ML, Naccarelli GV, Liao D. Premature cardiac contractions and risk of incident ischemic stroke. J Am Heart Assoc 2012;1:e002519.
25. Gladstone DJ, Dorian P, Spring M, Panzov V, Mamdani M, Healey JS et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE Trial. Stroke 2015;46:936-41.
26. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2n-9n.
27. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S et al; Investigators GR. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013;8:e63479.
28. Chiang CE, Naditch-Brule L, Murin J, Goethals M, Inoue H, O'Neill J et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythmia Electrophysiol 2012;5:632-9.
29. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014;16:308-19.
30. Lip GY, Laroche C, Boriani G, Dan GA, Santini M, Kalarus Z et al. Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2015;17:194-206.
31. Potpara TS, Dan GA, Trendafilova E, Goda A, Kusljugic Z, Manola S et al; Investigators B-A. Stroke prevention in atrial fibrillation and 0real world0 adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. Sci Rep 2016;6:20432.
32. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-94.
33. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
34. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013;167:1807-24.
35. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009;119:2146-52.
36. Grundvold I, Skretteberg PT, Liestol K, Erikssen G, Kjeldsen SE, Arnesen H et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension 2012;59:198-204.
37. Thomas MC, Dublin S, Kaplan RC, Glazer NL, Lumley T, Longstreth WT Jr et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens 2008;21:1111-6.
38. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 2014;35:1205-14.
39. Lip GY. Atrial fibrillation in patients with hypertension: trajectories of risk factors in yet another manifestation of hypertensive target organ damage. Hypertension 2016;68:544-5.
40. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003;41:218-23.
41. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009;373:739-45.
42. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011;107:85-91.
43. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc 2013;2:e000102.
44. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725-31.
45. Potpara TS, Stankovic GR, Beleslin BD, Polovina MM, Marinkovic JM, Ostojic MC et al. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. Chest 2012;141:339-47.
46. Chen K, Bai R, Deng W, Gao C, Zhang J, Wang X et al. HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter. Heart Rhythm 2015;12:1483-9.
47. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
48. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
49. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013;2:e000250.
50. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713-9.
51. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100.
52. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401.
53. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013;144:1555-63.
54. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A et al; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-9.
55. Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol 2013;168:4744-9.
56. Chatterjee S, Bavishi C, Sardar P, Agarwal V, Krishnamoorthy P, Grodzicki T et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. Am J Cardiol 2014;114:1049-52.
57. Richards TR, Tobe SW. Combining other antihypertensive drugs with betablockers in hypertension: a focus on safety and tolerability. Can J Cardiol 2014;30:S42-6.
58. Almenoff JS, DuMouchel W, Kindman LA, Yang X, Fram D. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf 2003;12:517-21.
59. Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med 1986;315:423-9.
60. Group KDIGOKBPW. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012;2:337-414.
61. Alexopoulos A, Perpinia A, Michelakakis N, Kossyvakis C, Deftereos S, Pyrgakis V. Evaluation of left ventricular hypertrophy in patients requiring permanent pacing. Ther Adv Cardiovasc Dis 2010;4:295-9.
62. Rienstra M, Van Veldhuisen DJ, Crijns HJ, Van Gelder IC; RACE Investigators. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. Eur Heart J 2007;28:741-51.
63. Okada R, Kawai S. Histopathology of the conduction system in sudden cardiac death. Jpn Circ J 1983;47:573-80.
64. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol 2008;52:686-717.
65. Emiroglu MY, Bulut M, Sahin M, Acar G, Akcakoyun M, Kargin R et al. Assessment of atrial conduction time in patients with essential hypertension. J Electrocardiol 2011;44:251-6.
66. Li Z, Dahlof B, Okin PM, Kjeldsen SE, Wachtell K, Ibsen H et al. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension study. J Hypertens 2008;26:1244-9.
67. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Jern S, Dahlof B et al. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2004;43:1029-34.
68. Dewland TA, Soliman EZ, Davis BR, Magnani JW, Yamal JM, Piller LB et al; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on conduction system disease. JAMA Intern Med 2016;176:1085-92.
69. Morin DP, Oikarinen L, Viitasalo M, Toivonen L, Nieminen MS, Kjeldsen SE et al. QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study. Eur Heart J 2009;30:2908-14.
70. Kannel WB. Vital epidemiologic clues in heart failure. J Clin Epidemiol 2000;53:229-35.
71. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823-30.
72. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-21.
73. Bohm M, Reil JC, Deedwania P, Kim JB, Borer JS. Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. Am J Med 2015;128:219-28.
74. Courand PY, Lantelme P. Significance, prognostic value and management of heart rate in hypertension. Arch Cardiovasc Dis 2014;107:48-57.
75. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/ trandolapril STudy (INVEST). Eur Heart J 2008;29:1327-34.
76. Fox K, Komajda M, Ford I, Robertson M, Bohm M, Borer JS et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J 2013;34:2263-70.
77. Olshansky B, Sullivan RM. Conventional management of inappropriate sinus tachycardia. J Interv Card Electrophysiol 2016;46:43-5.
78. Chouchou F, Pichot V, Pepin JL, Tamisier R, Celle S, Maudoux D et al. Sympathetic overactivity due to sleep fragmentation is associated with elevated diurnal systolic blood pressure in healthy elderly subjects: the PROOFSYNAPSE study. Eur Heart J 2013;34:2122-31, 2131a.
79. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet 2016;388:818-28.
80. Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJ, Van Veldhuisen DJ. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 2013;1:21-8.
81. Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW et al; Document reviewers. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making - A position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015;17:1169-96.
82. Spector P, Reynolds MR, Calkins H, Sondhi M, Xu Y, Martin A et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol 2009;104:671-7.
83. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
84. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation 2015;131:2176-84.
85. Binici Z, Intzilakis T, Nielsen OW, Kober L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation 2010;121:1904-11.
86. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al; 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Europace 2016;50:e1-88.
87. Potpara TS, Lane DA. Diving to the foot of an iceberg: the SEARCH for undiagnosed atrial fibrillation. Thromb Haemost 2014;112:1-3.
88. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110:213-22.
89. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCHAF study. Thromb Haemost 2014;111:1167-76.
90. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol 2015;66:985-96.
91. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C et al; ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014;129:2094-9.
92. Katritsis D, Boriani G, Garcia-Cosio F, Jas P, Josephson M, Hindricks G et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular rrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace 2017;19:465-511.
93. Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) Developed in Collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol 2003;42:1493-1531.
94. Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ et al. 2015 ACC/ AHA/HRS Guideline for the Management of Adult Patients With Supraventricular TachycardiaA Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016;67:e27-115.
95. Garnock-Jones KP. Esmolol. Drugs 2012;72:109-32.
96. Katritsis DG, Zografos T, Katritsis GD, Giazitzoglou E, Vachliotis V, Paxinos G et al. Catheter ablation vs. antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia: a randomized, controlled trial. Europace 2017;19:602-6.
97. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet 2016;388:806-17.
98. Fauchier L, Clementy N, Ivanes F, Angoulvant D, Babuty D, Lip G. Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated? Stroke 2016;47:1831-6.
99. Lip GY, Skjoth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 2015;114:826-34.
100. Lip GY, Nielsen PB. Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) be anticoagulated? yes: even 1 stroke risk factor confers a real risk of stroke. Circulation 2016;133:1498-503.
101. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA et al. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail 2015;17:570-82.
102. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012;125:2298-307.
103. Toyoda K, Yasaka M, Uchiyama S, Nagao T, Gotoh J, Nagata K et al; Bleeding with Antithrombotic Therapy Study Group. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study. Stroke 2010;41:1440-4.
104. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
105. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
106. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
107. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al; EAFTI. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;386:2093-104.
108. Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A et al. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY Trial). Am J Cardiol 2015;116:1204-9.
109. Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM et al; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc 2015;4. doi:10. 1161/JAHA. 115. 002015.
110. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc 2013;2:e004549.
111. Nault I, Miyazaki S, Forclaz A, Wright M, Jadidi A, Jais P et al. Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation. Eur Heart J 2010;31:1046-54.
112. Slavik RS, Tisdale JE, Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis 2001;44:121-52.
113. Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. Lancet 2016;388:829-40.
114. Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL et al; CONVERT Investigators. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 2008;300:1784-92.
115. Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost 2016;14:1711-4.
116. Zehender M, Meinertz T, Hohnloser S, Geibel A, Gerisch U, Olschewski M et al. Prevalence of circadian variations and spontaneous variability of cardiac disorders and ECG changes suggestive of myocardial ischemia in systemic arterial hypertension. Circulation 1992;85:1808-15.
117. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987;317:787-92.
118. Sideris DA. High blood pressure and ventricular arrhythmias. Eur Heart J 1993;14:1548-53.
119. Simpson RJ, Cascio WE, Crow RS, Schreiner PJ, Rautaharju PM, Heiss G. Association of ventricular premature complexes with electrocardiographicestimated left ventricular mass in a population of African-American and white men and women (The Atherosclerosis Risk in Communities. Am J Cardiol 2001;87:49-53.
120. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987;60:560-5.
121. Tempio D, Pruiti GP, Conti S, Romano SA, Tavano E, Capodanno D et al. Ventricular arrhythmias in aortic valve stenosis before and after transcatheter aortic valve implantation. Europace 2015;17:1136-40.
122. Calkins H, Maughan WL, Weisman HF, Sugiura S, Sagawa K, Levine JH. Effect of acute volume load on refractoriness and arrhythmia development in isolated, chronically infarcted canine hearts. Circulation 1989;79:687-97.
123. Kannel WB, Schatzkin A. Sudden death: Lessons from subsets in population studies. J Am Coll Cardiol 1985;5:141B-9B.
124. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Int Med 1988;108:7-13.
125. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998;32:1454-9.
126. Malmqvist K, Kahan T, Edner M, Bergfeldt L. Different actions of irbesartan and atenolol on cardiac repolarisation in hypertensive left ventricular hypertrophy. Am J Cardiol 2002;90:1107-12.
127. Ohtsuka S, Kakihana M, Watanabe H, Enomoto T, Ajisaka R, Sugishita Y. Alterations in left ventricular wall stress and coronary circulation in patients with isolated systolic hypertension. J Hypertens 1996;14:1349-55.
128. Manolis AJ, Beldekos D, Handansis S, Haralabidis G, Hatzissavas J, Foussas S et al. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. Am J Hypertens 1998;11:640-8.
129. Novo S. Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. Am J Hypertens 2001;14:637-43.
130. Mayet J, Chapman N, Shahi M, Poulter NR, Cunningham DA, Dave S et al. The effects on cardiac arrhythmias of antihypertensive therapy causing regression of left ventricular hypertrophy. Am J Hypertens 1997;10:611-8.
131. Siegel D, Hulley SB, Black DM, Cheitlin MD, Sebastian A, Seeley DG et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA 1992;267:1083-9.
132. Lumme JA, Jounela AJ. Cardiac arrhythmias in hypertensive outpatients on various diuretics. Correlation between incidence and serum potassium and magnesium levels. Ann Clin Res 1986;18:186-90.
133. Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereaux RB, Ibsen H et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death. The LIFE Study. Circulation 2007;116:700-5.
134. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852-7.
135. Osadchil OE. Mechanisms of hypokalemia-induced ventricular arrhythmogenicity. Fundam Clin Pharmacol 2010;24:547-59.
136. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008;51:393-8.
137. Lindholm LH, Dahlöf B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003;362:619-20.
138. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
139. Lee GK, Klarich KW, Grogan M, Cha YM. Premature ventricular contractioninduced cardiomyopathy: a treatable condition. Circ Arrhythm Electrophysiol 2012;5:229-36.
140. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010;7:865-9.
141. El Kadri M, Yokokawa M, Labounty T, Mueller G, Crawford T, Good E et al. Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy. Heart Rhythm 2015;12:706-13.
142. Saadeh AM, Evans SJ, James MA, Jones JV. QTc dispersion and complex ventricular arrhythmias in untreated newly presenting hypertensive patients. J Hum Hypertens 1999;13:665-9.
143. Galinier M, Balanescu S, Fourcade J, Dorobantu M, Boveda S, Massabuau P et al. Prognostic value of ventricular arrhythmias in systemic hypertension. J Hypertens 1997;15:1779-83.
144. Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Europace 2014;16:1257-83.
145. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al; Task Force for the Management of Patients with Ventricular A and the Prevention of Sudden Cardiac Death of the European Society of Cardiology. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace 2015;17:1601-87.
146. Blomstrom Lundqvist C, Auricchio A, Brugada J, Boriani G, Bremerich J, Cabrera JA et al; European Association of Cardiovascular I, Council of Cardiovascular I and European Society of Cardiac R. The use of imaging for electrophysiological and devices procedures: a report from the first European Heart Rhythm Association Policy Conference, jointly organized with the European Association of Cardiovascular Imaging (EACVI), the Council of Cardiovascular Imaging and the European Society of Cardiac Radiology. Europace 2013;15:927-36.
147. Boriani G, Diemberger I, Valzania C, Biffi M, Martignani C, Raschi E et al. Role of drugs and devices in patients at risk of sudden cardiac death. Fundam Clin Pharmacol 2010;24:575-94.
148. Sideris DA, Toumanidis ST, Anastasiou-Nana M, Zakopoulos N, Kitsiou A, Tsagarakis K et al. The circadian profile of extrasystolic arrhythmia: its relationship to heart rate and blood pressure. Int J Cardiol 1992;34:21-31.
149. Pringle SD, Dunn FG, Macfarlane PW, McKillop JH, Lorimer AR, Cobbe SM. Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1992;69:913-7.
150. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-67.
151. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009;54:1084-1091.
152. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
153. Aliot EM, Stevenson WG, Almendral-Garrote JM, Bogun F, Calkins CH, Delacretaz E et al. EHRA/HRS expert consensus on catheter ablation of ventricular arrhythmias. Europace 2009;11:771-817.
154. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E et al; Investigators D. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221-30.
155. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-62.
156. de Simone G, Devereux RB, Chinali M, Lee ET, Galloway JM, Barac A et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens 2010;28:353-60.
157. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011;13:18-28.
158. Losi MA, Izzo R, De Marco M, Canciello G, Rapacciuolo A, Trimarco V et al. Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: the Campania Salute Network. Int J Cardiol 2015;199:290-5.
159. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 2013;128:1085-93.
160. Shen S, He T, Chu J, He J, Chen X. Uncontrolled hypertension and orthostatic hypotension in relation to standing balance in elderly hypertensive patients. Clin Interv Aging 2015;10:897-906.
161. Low PA, Tomalia VA. Orthostatic hypotension: mechanisms, causes, management. J Clin Neurol 2015;11:220-6.
162. Ricci F, De Caterina R, Fedorowski A. Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. J Am Coll Cardiol 2015;66:848-60.
163. Milazzo V, Maule S, Di Stefano C, Tosello F, Totaro S, Veglio F et al. Cardiac organ damage and arterial stiffness in autonomic failure: comparison with essential hypertension. Hypertension 2015;66:1168-75.
164. Liu K, Wang S, Wan S, Zhou Y, Pan P, Wen B et al. Arterial stiffness, central pulsatile hemodynamic load, and orthostatic hypotension. J Clin Hypertens (Greenwich) 2016;18:655-62
165. Canney M, O'Connell MD, Murphy CM, O'Leary N, Little MA, O'Seaghdha CM et al. Single Agent Antihypertensive Therapy and Orthostatic Blood Pressure Behaviour in Older Adults Using Beat-to-Beat Measurements: The Irish Longitudinal Study on Ageing. PLoS One 2016;11:e0146156.
166. Nilsson D, Sutton R, Tas W, Burri P, Melander O, Fedorowski A. Orthostatic changes in hemodynamics and cardiovascular biomarkers in dysautonomic patients. PLoS One 2015;10:e0128962.
167. Jones PK, Shaw BH, Raj SR. Orthostatic hypotension: managing a difficult problem. Expert Rev Cardiovasc Ther 2015;13:1263-76.
168. Hughes M, Lip GY; Guideline Development Group NCGfMoAFiP, Secondary Care NIfH and Clinical E. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008;99:295-304.
169. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69:546-54.
170. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
171. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62.
172. Lauer A, Pfeilschifter W, Schaffer CB, Lo EH, Foerch C. Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurol 2013;12:394-405.
173. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007;120:700-5.
174. Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 2007;100:599-607.
175. Lip GY, Frison L, Grind M; Invetigators S. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007;28:752-9.
176. Angaran P, Dorian P, Tan MK, Kerr CR, Green MS, Gladstone DJ et al. The Risk stratification and stroke prevention therapy care gap in Canadian atrial fibrillation patients. Can J Cardiol 2016;32:336-43.
177. Steinberg BA, Kim S, Thomas L, Fonarow GC, Hylek E, Ansell J et al; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation I and Patients. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation 2014;129:2005-12.
178. Olesen JB, Lip GYH, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 0real world0 nationwide cohort study. Thromb Haemost 2011;106:739-49.
179. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011;4:14-21.
180. Lip GY, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65:1385-94.
181. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015;65:635-42.
182. Lahaye S, Regpala S, Lacombe S, Sharma M, Gibbens S, Ball D et al. Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014;111:465-73.
183. Elliott WJ. The economic impact of hypertension. J Clin Hypertens (Greenwich) 2003;5:3-13.
184. Boriani G, Maniadakis N, Auricchio A, Muller-Riemenschneider F, Fattore G, Leyva F et al. Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. Eur Heart J 2013;34:1869-74.
185. Hannon N, Callaly E, Moore A, Ni Chroinin D, Sheehan O, Marnane M et al. Improved late survival and disability after stroke with therapeutic anticoagulation for atrial fibrillation: a population study. Stroke 2011;42:2503-8.
186. Bruggenjurgen B, Rossnagel K, Roll S, Andersson FL, Selim D, Muller-Nordhorn J et al. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health 2007;10:137-43.
187. Cotte FE, Chaize G, Kachaner I, Gaudin AF, Vainchtock A, Durand-Zaleski I. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France. J Stroke Cerebrovasc Dis 2014;23:e73-83.
188. Kasmeridis C, Apostolakis S, Ehlers L, Rasmussen LH, Boriani G, Lip GY. Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants. Pharmacoeconomics 2013;31:971-80.
189. Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T et al. Costeffectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J 2014;35:1897-906.